Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status

202193 citationsJournal Articlehybrid Open Access

Authors

Shigeharu Fujieda · University of Fukui

Shoji Matsune · Nippon Medical School Musashi Kosugi Hospital

Sachio Takeno · Hiroshima University

Nobuo Ohta · Tohoku Medical and Pharmaceutical University

Mikiya Asako · Kansai Medical University

Claus Bachert · Karolinska Institutet

Tomoyuki Inoue

Abstract

Dupilumab produced consistent improvement in symptoms of severe CRSwNP irrespective of ECRS status. Therefore, blood eosinophil level may not be a suitable biomarker for dupilumab efficacy in CRSwNP.

Topics & Keywords

Sinusitis and nasal conditions Allergic Rhinitis and Sensitization Asthma and respiratory diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Allergy

Volume 77, Issue 1, pp. 186-196

DOI: 10.1111/all.14906

Field-Weighted Citation Impact: 13.28